Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Modified vaccinia Ankara (MVA) was evaluated as an alternative to Dryvax in vaccinia-naïve and vaccinia-immune adult volunteers. Subjects received intramuscular MVA or placebo followed by Dryvax challenge at 3 months. Two or more doses of MVA prior to Dryvax reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax vaccinia-specific CD8(+) T cell responses and extracellular enveloped virus protein-specific antibody responses. MVA vaccination is safe and immunogenic and improves the safety and immunogenicity of subsequent Dryvax vaccination supporting the potential for using MVA as a vaccine in the general population to improve immunity to orthopoxviruses.
Parrino
Janie
J
Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
McCurdy
Lewis H
LH
Larkin
Brenda D
BD
Gordon
Ingelise J
IJ
Rucker
Steven E
SE
Enama
Mary E
ME
Koup
Richard A
RA
Roederer
Mario
M
Bailer
Robert T
RT
Moodie
Zoe
Z
Gu
Lin
L
Yan
Lihan
L
Graham
Barney S
BS
D000293:Adolescent; D000328:Adult; D000917:Antibody Formation / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D004311:Double-Blind Method; D006801:Humans; D008875:Middle Aged; D012899:Smallpox / Q000517:prevention & control*; D012900:Smallpox Vaccine / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology*
C078786:DryVax vaccine; D012900:Smallpox Vaccine